<sup>18</sup>F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use

Leupe, Hannes; Ahenkorah, Stephen; Dekervel, Jeroen; Unterrainer, Marcus; Van Cutsem, Eric; Verslype, Chris; Cleeren, Frederik; Deroose, Christophe M.

doi:10.2967/jnumed.123.265622

Cited by 16 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SSTR positron emission tomography (PET) is commonly performed through 68 Ga-SSTRS agonists with overall sensitivity and specificity of 97% and 95.1% in detecting NENs. 68 Ga-SSTR agonists, however, are associated with high background uptake in the liver and low spatial resolution, which might hamper detection of subcentimeter liver metastases 6,7,9 …”

Section: Therapeutic Approaches Based On Locationmentioning

confidence: 99%

“…The above limitations are mitigated in the case of 18 F and 64 Cu-SSTR agonists, with the 64 Cu agonist recently Food and Drug Administration approved. Additionally, SSTR antagonists, which are not Food and Drug Administration approved, given higher binding receptor density and low internalization, outperform SSTR agonist, with reported sensitivity up to 91.7% compared with 77.2% for SSTR agonists when evaluating same cohort of patients, despite some limitations in assessing osseous metastases 6,7,9–14 …”

Section: Therapeutic Approaches Based On Locationmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Intricacies and Advances in Neuroendocrine Tumors: An Organ-Based Multidisciplinary Approach

Asmundo,

Ambrosini,

Anderson

et al. 2024

J Comput Assist Tomogr

View full text Add to dashboard Cite

Neuroendocrine neoplasms (NENs) are rare neoplasms originating from neuroendocrine cells, with increasing incidence due to enhanced detection methods. These tumors display considerable heterogeneity, necessitating diverse management strategies based on factors like organ of origin and tumor size. This article provides a comprehensive overview of therapeutic approaches for NENs, emphasizing the role of imaging in treatment decisions. It categorizes tumors based on their locations: gastric, duodenal, pancreatic, small bowel, colonic, rectal, appendiceal, gallbladder, prostate, lung, gynecological, and others. The piece also elucidates the challenges in managing metastatic disease and controversies surrounding MEN1–neuroendocrine tumor management. The article underscores the significance of individualized treatment plans, underscoring the need for a multidisciplinary approach to ensure optimal patient outcomes.

show abstract

Section: Therapeutic Approaches Based On Locationmentioning

confidence: 99%

Section: Therapeutic Approaches Based On Locationmentioning

confidence: 99%

Clinical Intricacies and Advances in Neuroendocrine Tumors: An Organ-Based Multidisciplinary Approach

Asmundo,

Ambrosini,

Anderson

et al. 2024

J Comput Assist Tomogr

View full text Add to dashboard Cite

show abstract

Engineering peptide drug therapeutics through chemical conjugation and implication in clinics

Rizvi,

Zhang,

Fang

2024

Medicinal Research Reviews

View full text Add to dashboard Cite

The development of peptide drugs has made tremendous progress in the past few decades because of the advancements in modification chemistry and analytical technologies. The novel‐designed peptide drugs have been modified through various biochemical methods with improved diagnostic, therapeutic, and drug‐delivery strategies. Researchers found it a helping hand to overcome the inherent limitations of peptides and bring continued advancements in their applications. Furthermore, the emergence of peptide‐drug conjugates (PDCs)—utilizes target‐oriented peptide moieties as a vehicle for cytotoxic payloads via conjugation with cleavable chemical agents, resulting in the key foundation of the new era of targeted peptide drugs. This review summarizes the various classifications of peptide drugs, suitable chemical modification strategies to improve the ADME (adsorption, distribution, metabolism, and excretion) features of peptide drugs, and recent (2015–early 2024) progress/achievements in peptide‐based drug delivery systems as well as their fruitful implication in preclinical and clinical studies. Furthermore, we also summarized the brief description of other types of PDCs, including peptide‐MOF conjugates and peptide‐UCNP conjugates. The principal aim is to provide scattered and diversified knowledge in one place and to help researchers understand the pinching knots in the science of PDC development and progress toward a bright future of novel peptide drugs.

show abstract

New Radiopharmaceuticals for Brain Tumors Imaging

Holzgreve,

Albert

2024

Advanced Imaging and Therapy in Neuro-Oncology

View full text Add to dashboard Cite

¹⁸F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use

Cited by 16 publications

References 42 publications

Clinical Intricacies and Advances in Neuroendocrine Tumors: An Organ-Based Multidisciplinary Approach

Clinical Intricacies and Advances in Neuroendocrine Tumors: An Organ-Based Multidisciplinary Approach

Engineering peptide drug therapeutics through chemical conjugation and implication in clinics

New Radiopharmaceuticals for Brain Tumors Imaging

Contact Info

Product

Resources

About

18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use

Cited by 16 publications

References 42 publications

Clinical Intricacies and Advances in Neuroendocrine Tumors: An Organ-Based Multidisciplinary Approach

Clinical Intricacies and Advances in Neuroendocrine Tumors: An Organ-Based Multidisciplinary Approach

Engineering peptide drug therapeutics through chemical conjugation and implication in clinics

New Radiopharmaceuticals for Brain Tumors Imaging

Contact Info

Product

Resources

About

¹⁸F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use